Immix Biopharma Files 8-K: Material Agreement & Exhibits
Ticker: IMMX · Form: 8-K · Filed: Jun 3, 2025 · CIK: 1873835
Sentiment: neutral
Topics: material-agreement, filing, exhibits
Related Tickers: IMMX
TL;DR
Immix Biopharma (IMMX) filed an 8-K on 6/3/25 for a material definitive agreement and exhibits.
AI Summary
On June 3, 2025, Immix Biopharma, Inc. filed an 8-K report. The filing indicates an entry into a material definitive agreement and includes financial statements and exhibits. The company is incorporated in Delaware and its principal executive offices are located in Los Angeles, California.
Why It Matters
This 8-K filing signals a significant development for Immix Biopharma, Inc., potentially involving a new material agreement that could impact its business operations and financial standing.
Risk Assessment
Risk Level: medium — The filing of a material definitive agreement suggests a significant business event, the details of which could carry substantial risk or reward for the company.
Key Numbers
- 20250603 — Filing Date (The report was filed on this date.)
Key Players & Entities
- Immix Biopharma, Inc. (company) — Registrant
- June 3, 2025 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of Incorporation
- 11400 West Olympic Blvd., Suite 200, Los Angeles, CA 90064 (address) — Principal executive offices
- 001-41159 (company_id) — Commission File Number
FAQ
What is the nature of the material definitive agreement entered into by Immix Biopharma, Inc.?
The filing does not specify the details of the material definitive agreement, only that one was entered into on or before June 3, 2025.
What other information is included in this 8-K filing?
In addition to the material definitive agreement, the filing includes financial statements and exhibits.
When was Immix Biopharma, Inc. incorporated?
Immix Biopharma, Inc. was incorporated in Delaware.
What is the primary business of Immix Biopharma, Inc. according to its SIC code?
The Standard Industrial Classification (SIC) code for Immix Biopharma, Inc. is 2834, which corresponds to Pharmaceutical Preparations.
What is the address of Immix Biopharma, Inc.'s principal executive offices?
The principal executive offices of Immix Biopharma, Inc. are located at 11400 West Olympic Blvd., Suite 200, Los Angeles, CA 90064.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on June 3, 2025 regarding Immix Biopharma, Inc. (IMMX).